Criteria* | Description and implementation |
---|---|
High adherence to index drug (required) | For etanercept, adalimumab and oral medications, must be ≥ 80% adherent to therapy, calculated as a medication possession ratio [38] |
 | For infliximab, must have received at least the number of infusions expected between the index and outcome visit dates to conform to a schedule of 0, 2, 6 and 14 weeks and every 8 weeks thereafter |
 | For abatacept, must have received the number of infusions expected between the index and outcome visit dates to conform to a schedule of once-monthly dosing; missing one infusion is permissible |
 | For rituximab, criterion is not applicable |
Biologic switch or add (prohibited) | Between the index and outcome visit dates, patient cannot initiate therapy with a new biologic agent |
Addition of a new nonbiologic DMARD (prohibited) | Between the index and outcome visit dates, patient cannot initiate therapy with a new nonbiologic DMARD (methotrexate, sulfasalazine, leflunomide or hydroxychloroquine) that they were not already taking during the 6 months prior to the index date |
Increase in biologic dose or frequency (prohibited) | For etanercept and adalimumab, dose escalation of etanercept to 50 mg twice weekly or adalimumab 40 mg once weekly is prohibited |
 | For infliximab, difference between ending and starting dose, with each dose rounded up to the nearest 100 mg cannot be ≥ 100 mg. The number of infusions must be within 120% of the number expected assuming a 0-, 2-, or 6-week load and an 8-week infusion schedule |
 | For abatacept, difference between ending and starting dose cannot be ≥ 100 mg |
 | For rituximab, criterion is not applicable |
More than one glucocorticoid joint injection (prohibited) | Cannot receive glucocorticoid injections†on more than one unique calendar day between the index date + 90 days and the outcome visit date, inclusive |
Increase in dose of oral glucocorticoid (prohibited) | For patients who received no prescriptions for oral glucocorticoids during the 6 months prior to the index date, cannot have received more than 30 days of oral glucocorticoids between the index date + 90 days and the outcome visit date, inclusive |
 | For patients who received prescriptions for oral glucocorticoids in the 6 months prior to the index date, the cumulative glucocorticoid dose in the 6 months prior to the outcome visit date must be similar (that is, within 120%) to the cumulative dose in the 6 months prior to the index visit date |